膝骨关节炎治疗药物——lorecivivint  

A novel drug for knee osteoarthritis:lorecivivint

作　　者：陈婕 杨军 田娜娜 陈媛 广梅 范慧君 王红军 CHEN Jie;YANG Jun;TIAN Nana;CHEN Yuan;GUANG Mei;FAN Huijun;WANG Hongjun(Innovative Product Department,Beijing Tide Pharmaceutical Co.,Ltd.,Beijing 100176,China)

机构地区：[1]北京泰德制药股份有限公司创新药部,北京100176

出　　处：《临床药物治疗杂志》2024年第6期6-13,共8页Clinical Medication Journal

摘　　要：lorecivivint是一种调节Wnt通路CLK/DYRK激酶的新型小分子抑制剂,通过关节腔注射给药,治疗膝骨关节炎,目前正在美国进行Ⅲ期临床试验。已完成的临床试验结果显示,lorecivivint安全性和耐受性良好,具有缓解疼痛和改善膝关节功能的显著疗效,长期治疗可改善关节结构,是具有潜力的疾病改善型骨关节炎药物。本文就lorecivivint的基本信息、作用机制、药动学和临床研究进展等方面进行概述。Lorecivivint is a novel small-molecule inhibitor that modulates the Wnt pathway through CLK/DYRK kinase.It is administered through intra-articular injection for the treatment of knee osteoarthritis.Phase II clinical trials for lorecivivint are currently underway in the United States.Completed clinical trials have demonstrated that lorecivivint has good safety and tolerability,with significant efficacy in pain relief and improvement of knee joint function.Long-term treatment has shown potential in improving joint structure,making it a promising disease-modifying osteoarthritis drug.This article provides an overview of the basic information,mechanism of action,pharmacokinetics and clinical research progress of lorecivivint.

关 键 词：lorecivivint WNT通路 CLK/DYRK激酶抑制剂 膝骨关节炎 疾病改善型骨关节炎药物 

分 类 号：R982[医药卫生—药品]